CN103405603A - Composite drug composition for treating anemia - Google Patents
Composite drug composition for treating anemia Download PDFInfo
- Publication number
- CN103405603A CN103405603A CN2013103755600A CN201310375560A CN103405603A CN 103405603 A CN103405603 A CN 103405603A CN 2013103755600 A CN2013103755600 A CN 2013103755600A CN 201310375560 A CN201310375560 A CN 201310375560A CN 103405603 A CN103405603 A CN 103405603A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix
- parts
- drug compositions
- combination drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a composite drug composition, which is prepared from a plurality of components as follows: astragalus membranaceus, angelica sinensis, white atractylodes rhizome, liquorice, tuckahoe, turtle shell, rhizoma pinellinae praeparata, lithospermum, double blossom, sea otter, fruit of Chinese wolfberry, caulis spatholobi, composite iron, an assistant and an additive in a compounding manner. The drug composition displays excellent performance of rapidly treating alimentary anemia by right choice and specific combination of the components, especially has the advantages of Chinese and western medicines, and has a wide potential market prospect and medical value.
Description
Technical field
The present invention relates to a kind of pharmaceutical composition for the treatment of anemia, relate more specifically to a kind of combination drug compositions for the treatment of nutritional anemia.
Background technology
Anemia is a kind of common clinical, frequently-occurring disease, usually shows giddy, tinnitus, headache, insomnia, dreaminess, hypomnesis and the symptom such as absent minded.During infantile anemia, even also can affect the growth of its intelligence.According to World Health Organization's statistics, the whole world approximately has 3,000,000,000 people to have Anemia in various degree, and cause dead number especially nearly up to ten million because the trouble anemia causes various diseases every year.Common nutritional anemia is mainly by iron deficiency anemia, megaloblastic anemia, Combination anemia etc., and especially iron deficiency anemia and chronic nephropathy, heart disease are interrelated.
Up to the present, the existing many reports of the pharmaceutical composition of relevant treatment anemia:
The patent of CN102784230A discloses a kind of pharmaceutical composition for the treatment of nutritional anemia, it comprises the Radix Astragali, Arillus Longan, Radix Angelicae Sinensis, Colla Corii Asini, glucose saccharic acid ferrous iron, brown sugar (Saccharum Sinensis Roxb.) and adjuvant, and it has advantages of the safety of use, determined curative effect, simple, the applicable suitability for industrialized production of technique.
The patent of CN102188607A discloses a kind of pharmaceutical composition for the treatment of aplastic anemia, and it comprises a certain proportion of following component: Radix Ginseng Rubra, the Radix Astragali, Radix Pseudostellariae, Cordyceps, Radix Salviae Miltiorrhizae, Radix Polygoni Multiflori, Radix Rehmanniae Preparata, Carapax et Plastrum Testudinis, Colla Corii Asini, Carapax Trionycis, Radix Ophiopogonis, Rhizoma Alismatis, Cornu Cervi Degelatinatum, Flos Lonicerae, Radix Glycyrrhizae, Fructus Lycii.This medicine composite for curing successful, cure rate is high and have no side effect.
The patent of CN101342343A discloses a kind of pharmaceutical composition for the treatment of anemia, it comprises Radix Codonopsis water extract, Rhizoma Dioscoreae water extract, Semen Coicis water extract, Pericarpium Citri Reticulatae water extract, Rhizoma Pinelliae Preparatum water extract, Semen Alpiniae Katsumadai water extract, Fructus Jujubae water extract, ferrous sulfate, Radix Glycyrrhizae extractum, and it is applied to treat the effect that anemia has invigorating the spleen and regulating the stomach, QI invigorating and blood producing.
The patent of CN1872236A discloses a kind of Chinese medicine composition for the treatment of aplastic anemia, and said composition comprises Radix Ginseng, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Fructus Lycii, Os Draconis, Flos Lonicerae, Gypsum Fibrosum, Colla Corii Asini, Colla cornus cervi, Carapax Trionycis, Radix Codonopsis, Fructus Ligustri Lucidi, Semen Cuscutae, the Pseudobulbus Bletillae (Rhizoma Bletillae), Poria, Fructus Jujubae, Radix Glycyrrhizae.It can effectively protect the effect of human normal cell and bone marrow, repairs the normal cell of due to illness poison infringement and the damage of each system, can improve rapidly immunologic function.
The pharmaceutical composition of existing treatment anemia mostly is traditional Chinese medicine composition, it has property of medicine gentleness, toxic and side effects is few, applied widely, and can be from improving in essence the function of clinical symptoms, conditioning physical function and raising resistance, thereby can reach the beneficial effect for the treatment of both the principal and secondary aspects of a disease, but have equally slow curative effect, effect not obviously, medicine time long drawback.As everyone knows, doctor trained in Western medicine or western medicine adopt the strategy of oral or injection and show that onset is short, the obvious advantage of curative effect, cause easily that but gastrointestinal tract, neural untoward reaction, zest are stronger, existing Chinese-western composite medicine compositions also is difficult to meet the application demand of medical system and medical research simultaneously.
Advantage for the existing existing defect of Chinese medicine composition therapy and western medicine, the present invention is intended to prepare a kind of novel compound Pharmaceutical composition, suitable selection and particular combinations by component, make pharmaceutical composition show the excellent properties for the treatment of nutritional anemia, especially had each side's advantage of Chinese and western medicine concurrently, show advantage rapid-action, evident in efficacy, have wide market prospect and medical value.
Summary of the invention
For many defects of above-mentioned existence, the inventor conducts in-depth research this, after having paid sufficient creative work and having explored through further investigation, thereby has completed the present invention.
Particularly, the present invention relates generally to the content of three aspects:.
First aspect, the present invention relates to a kind of combination drug compositions, described combination drug compositions is composited by the Radix Astragali, Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Poria, Carapax Trionycis, Rhizoma Pinelliae Preparatum, Radix Arnebiae (Radix Lithospermi), Flos Lonicerae, Solenognathus, Fructus Lycii, Caulis Spatholobi, compound iron, auxiliary agent and additive various ingredients.
As a kind of exemplary exemplifying, in described combination drug compositions, in weight portion, its concrete constituent content is as follows:
| The Radix Astragali | 10-20 |
| Radix Angelicae Sinensis | 10-20 |
| The Rhizoma Atractylodis Macrocephalae | 5-10 |
| Radix Glycyrrhizae | 1-5 |
| Poria | 2-6 |
| Carapax Trionycis | 1-5 |
| Rhizoma Pinelliae Preparatum | 5-10 |
| Radix Arnebiae (Radix Lithospermi) | 5-10 |
| Flos Lonicerae | 1-5 |
| Solenognathus | 5-10 |
| Fructus Lycii | 10-15 |
| Caulis Spatholobi | 10-15 |
| Compound iron | 0.1-0.5 |
| Auxiliary agent | 0.5-1.0 |
| Additive | 0.5-1.5 |
。
In described combination drug compositions of the present invention, the parts by weight of the Radix Astragali are 10-20 part, as are 10 parts, 12 parts, 14 parts, 16 parts, 18 parts or 20 parts.
In described combination drug compositions of the present invention, the parts by weight of Radix Angelicae Sinensis are 10-20 part, as are 10 parts, 12 parts, 14 parts, 16 parts, 18 parts or 20 parts.
In described combination drug compositions of the present invention, the parts by weight of the Rhizoma Atractylodis Macrocephalae are 5-10 part, as are 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts.
In described combination drug compositions of the present invention, the parts by weight of Radix Glycyrrhizae are 1-5 part, as are 1 part, 2 parts, 3 parts, 4 parts or 5 parts.
In described combination drug compositions of the present invention, the parts by weight of Poria are 2-6 part, as are 2 parts, 3 parts, 4 parts, 5 parts or 6 parts.
In described combination drug compositions of the present invention, the parts by weight of Carapax Trionycis are 1-5 part, as are 1 part, 2 parts, 3 parts, 4 parts or 5 parts.
In described combination drug compositions of the present invention, the parts by weight of Rhizoma Pinelliae Preparatum are 5-10 part, as are 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts.
In described combination drug compositions of the present invention, the parts by weight of Radix Arnebiae (Radix Lithospermi) are 5-10 part, as are 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts.
In described combination drug compositions of the present invention, the parts by weight of Flos Lonicerae are 1-5 part, as are 1 part, 2 parts, 3 parts, 4 parts or 5 parts.
In described combination drug compositions of the present invention, the parts by weight of Solenognathus are 5-10 part, as are 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts.
In described combination drug compositions of the present invention, the parts by weight of Fructus Lycii are 10-15 part, as are 10 parts, 11 parts, 12 parts, 13 parts, 14 parts or 15 parts.
In described combination drug compositions of the present invention, the parts by weight of Caulis Spatholobi are 10-15 part, as are 10 parts, 11 parts, 12 parts, 13 parts, 14 parts or 15 parts.
In described combination drug compositions of the present invention, the parts by weight of compound iron are 0.1-0.5 part, as are 0.1 part, 0.2 part, 0.3 part, 0.4 part or 0.5 part, and described compound iron is chitosan ferrum (III) coordination compound.
In described combination drug compositions of the present invention, the auxiliary agent parts by weight are 0.5-1.0 part, as it is 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part or 1.0 parts, described auxiliary agent is the mixture of 4-methoxy cinnamic acid, p-Methoxybenzoic acid, 3-amylbenzene sodium acetate, in weight ratio, the ratio of described 4-methoxy cinnamic acid, p-Methoxybenzoic acid and 3-amylbenzene acetic acid is 1:1-2:1-1.5, is preferably 1:1:1.
In described combination drug compositions of the present invention, the weight of additive umber is 0.5-1.5 part, as it is 0.5 part, 0.6 part, 0.7 part, 0.8 part, 0.9 part, 1.0 parts, 1.1 parts, 1.2 parts, 1.3 parts, 1.4 parts or 1.5 parts, described additive is the mixture of the chelating ferrous and maltodextrin of carbamoylglycine dipeptides, in weight ratio, chelating ferrous and ratio maltodextrin of described carbamoylglycine dipeptides is 1:1-1.5, is preferably 1:1.
Second aspect, the present invention relates to the preparation method of above-mentioned combination drug compositions, and concrete steps are as follows:
(A) preparation of Radix Astragali extract, Radix Angelicae Sinensis extract, Rhizoma Atractylodis Macrocephalae extract, Radix Glycyrrhizae extract, Poria extract, Carapax Trionycis extract, Rhizoma Pinelliae Preparatum extract, Radix Arnebiae extract, Flos Lonicerae extract, Solenognathus extract, Fructus Lycii extract, Caulis Spatholobi extract
Respectively above-mentioned medical material is pulverized after dry in the sun, adopting mass percent concentration is the ethanol of 50-60%, at 60-65 ℃ of lower reflux, extract, 3-5 hour, simmer down to extractum after reclaiming ethanol, again drying, pulverize, grind to form fine powder, cross 80 mesh sieves, thereby obtain respectively the extract of said medicine active component, standby.
(B) preparation of compound iron
The preparation of employing conventional method, its step is as follows: the chitosan of getting deacetylation>=95% is dissolved in the acetic acid solution that mass concentration is 1-3%, stir into transparent uniform solution, take the ammonium ferric sulfate with chitosan monomer equimolar amounts, soluble in water, stir, it is 1-2 that dilute sulfuric acid and ammonia are regulated its pH, under stirring, the ammonium ferric sulfate aqueous solution is slowly added in the acetic acid solution of chitosan, reaction 3-5h, after reaction finishes, separate out chitosan ferrum (III) coordination compound gel, staticly settle fully, centrifugalize, the lower sediment deionized water, dehydrated alcohol cyclic washing to inspection does not measure Fe
3+existence, clean postprecipitation through lyophilization, obtain required compound iron, standby.
(C) preparation of auxiliary agent
Proportionally take 4-methoxy cinnamic acid, p-Methoxybenzoic acid, 3-amylbenzene sodium acetate mix homogeneously, obtain auxiliary agent, standby.
(D) preparation of additive
Get the 50-100g glycine and the 30-50g potassium cyanate mixes, add water 100-200ml, adding 2-3gKOH, room temperature reaction fully after, with hydrochloric acid, be adjusted to pH=4-5, low temperature crystallization, filter to obtain the carbamoylglycine dipeptides; Get carbamoylglycine dipeptides 50-60g, ferrous sulfate 25-40g, add water 100-150ml, with sodium hydroxide, regulate pH=6-7, after 60-80 ℃ of heating in water bath 5-7h, filter, filtrate processing industry ethanol, separate out precipitation, and it is chelating ferrous that oven dry obtains the carbamoylglycine dipeptides; Then take by a certain percentage the chelating ferrous and maltodextrin mix homogeneously of carbamoylglycine dipeptides and namely obtain desired additives, standby.
(E) according to above-mentioned weight portion, take each component mix homogeneously, obtain combination drug compositions of the present invention.
In addition, in described combination drug compositions of the present invention, also can add pharmaceutically acceptable adjuvant or excipient to be prepared into various dosage forms, such as oral liquid, tablet, pill etc., be preferably pill, more preferably water-honeyed pill; For example, every 200g gained mix powder refined honey 50g, then add after water stirs and make water-honeyed pill, dry product.For the selection of adjuvant or excipient, those skilled in the art can carry out according to the requirement of pharmacy type, and the present invention has no particular limits.
The third aspect, the present invention relates to above-mentioned combination drug compositions for the preparation of the purposes in treatment anemia medicine, is preferred for preparing the purposes in treatment nutritional anemia medicine.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.
Preparation example 1
Respectively the Radix Astragali, Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Poria, Carapax Trionycis, Rhizoma Pinelliae Preparatum, Radix Arnebiae (Radix Lithospermi), Flos Lonicerae, Solenognathus, Fructus Lycii, Caulis Spatholobi are pulverized after dry in the sun, the employing mass percent concentration is 60% ethanol, 60 ℃ of lower reflux, extract, 5 hours, simmer down to extractum after reclaiming ethanol, again drying, pulverize, grind to form fine powder, cross 80 mesh sieves, thereby obtain respectively the extract of said medicine active component, standby.
Preparation example 2
(molecular weight is 179.17g/mol to get the chitosan of 10g deacetylation>=95%, Aladdin reagent) being dissolved in the 500ml mass concentration is in 3% acetic acid solution, stir into transparent uniform solution, take the ammonium ferric sulfate with chitosan monomer equimolar amounts, soluble in water, stir, it is 1.8 that dilute sulfuric acid and ammonia are regulated its pH, under stirring, the ammonium ferric sulfate aqueous solution is slowly added in the acetic acid solution of chitosan, reaction 5h, after reaction finishes, separate out chitosan ferrum (III) coordination compound gel, staticly settle fully, centrifugalize, the lower sediment deionized water, dehydrated alcohol cyclic washing to inspection does not measure Fe
3+existence, clean postprecipitation through lyophilization, obtain required compound iron, standby.
Preparation example 3
In weight ratio, according to the 1:1:1 ratio, take 4-methoxy cinnamic acid, p-Methoxybenzoic acid, each 5g mix homogeneously of 3-amylbenzene sodium acetate, obtain auxiliary agent, standby.
Preparation example 4
Get the 60g glycine and the 40g potassium cyanate mixes, add water 100ml, adding 2.5gKOH, room temperature reaction fully after, with hydrochloric acid, be adjusted to pH=4.5, low temperature crystallization, filter to obtain the carbamoylglycine dipeptides; Get carbamoylglycine dipeptides 60g, ferrous sulfate 35g, add water 120ml, regulates pH=6.7 with sodium hydroxide, after 75 ℃ of heating in water bath 6h, filters, and filtrate processing industry ethanol, separate out precipitation, and it is chelating ferrous that oven dry obtains the carbamoylglycine dipeptides; Then take chelating ferrous and each 25g mix homogeneously of maltodextrin of carbamoylglycine dipeptides and namely obtain desired additives, standby.
Embodiment 1
Take above-mentioned each component prepared, Radix Astragali 15g, Radix Angelicae Sinensis 20g, Rhizoma Atractylodis Macrocephalae 8g, Radix Glycyrrhizae 3g, Poria 5g, Carapax Trionycis 2g, Rhizoma Pinelliae Preparatum 8g, Radix Arnebiae (Radix Lithospermi) 6g, Flos Lonicerae 4g, Solenognathus 5g, Fructus Lycii 12g, Caulis Spatholobi 14g, compound iron 0.5g, auxiliary agent 0.9g and additive 1.2g mix homogeneously, obtain combination drug compositions of the present invention, called after FH-1.
Embodiment 2
Take above-mentioned each component prepared, Radix Astragali 20g, Radix Angelicae Sinensis 18g, Rhizoma Atractylodis Macrocephalae 6g, Radix Glycyrrhizae 5g, Poria 3g, Carapax Trionycis 3g, Rhizoma Pinelliae Preparatum 5g, Radix Arnebiae (Radix Lithospermi) 10g, Flos Lonicerae 2g, Solenognathus 9g, Fructus Lycii 13g, Caulis Spatholobi 10g, compound iron 0.2g, auxiliary agent 0.6g and additive 1.5g mix homogeneously, obtain combination drug compositions of the present invention, called after FH-2.
Embodiment 3
Take above-mentioned each component prepared, Radix Astragali 10g, Radix Angelicae Sinensis 15g, Rhizoma Atractylodis Macrocephalae 10g, Radix Glycyrrhizae 2g, Poria 6g, Carapax Trionycis 5g, Rhizoma Pinelliae Preparatum 10g, Radix Arnebiae (Radix Lithospermi) 7g, Flos Lonicerae 3g, Solenognathus 8g, Fructus Lycii 10g, Caulis Spatholobi 12g, compound iron 0.4g, auxiliary agent 0.75g and additive 0.9g mix homogeneously, obtain combination drug compositions of the present invention, called after FH-3.
Comparative Examples 1
Except not adding compound iron, in the mode of embodiment 1, implemented Comparative Examples 1 respectively, obtain control drug compositions D1.
Comparative Examples 2
Except not adding auxiliary agent, with embodiment 1, implemented Comparative Examples 2 respectively, obtain control drug compositions D2.
Comparative Examples 3
Except not adding additive, in the mode of embodiment 1, implemented Comparative Examples 3 respectively, obtain control drug compositions D3.
Comparative Examples 4
Except not adding 3-amylbenzene sodium acetate, in the mode of embodiment 1, implemented Comparative Examples 4 respectively, obtain control drug compositions D4.
Comparative Examples 5
Except not adding the 4-methoxy cinnamic acid, in the mode of embodiment 1, implemented Comparative Examples 5 respectively, obtain control drug compositions D5.
Comparative Examples 6
Except not adding p-Methoxybenzoic acid, in the mode of embodiment 1, implemented Comparative Examples 6 respectively, obtain control drug compositions D6.
The performance test experiment
The research of combination drug compositions of the present invention to rat nutritional anemia therapeutic efficiency.
Experiment material: the pharmaceutical composition that the embodiment of the present invention 1 is prepared; Male Wistar rat, body weight 80-100g.
Experimental apparatus: atomic absorption spectrophotometer (SpectrumAA-20 type), Hb1002 hemoglobin tester, FT-630-γ-enumerator.
Experimental technique:
50 of Wistar rats, feed and hang down the iron base feedstuff, 3 weeks of consumption, preparation nutritional anemia animal model, through the tail venous blood sampling, Measuring hemoglobin content, when content of hemoglobin during lower than 100g/L, rat is divided into to iron deficiency matched group (the low iron base feedstuff of feeding) at random, model group (the low iron base feedstuff of feeding, every day gavage ferrous sulfate 680mg/kg) and pharmaceutical composition of the present invention low, in, high dose group (the low iron base feedstuff of feeding, every day, gavage gave respectively pharmaceutical composition FH-1 of the present invention, consumption is respectively 260, 450, 680mg/kg), totally 5 groups, every group 10, 4 weeks of successive administration.When experiment finishes, use the etherization rat, after abdominal aortic blood, win liver and spleen, be placed in refrigerator standby.
(1) hemoglobin (Hb) adopts HemoCue Measuring hemoglobin content, with 10 μ l quantitative capillary tubes, get rat tail blood, put into the plastic tube that fills 2.5ml high-potassium ferricyanide reagent, fully vibration, make the complete stripping of blood, after lucifuge is placed 15min, measure with Hemoglobin Meter, simultaneously Measuring hemoglobin standard and primary standard substance.
(2) in liver, spleen tissue, ferrum is got about 0.2g tissue and is put into the teat glass through the hydrochloric acid dry cleansing, add nitric acid: perchloric acid (weight ratio 4:1) mixed acid 2ml, after digestion, with deionized water, be settled to 5ml or 10ml, adopt flame atomization to measure iron content in tissue, each mensuration with Hepar Bovis seu Bubali powder (NBS1577a of NBS) as the Quality Control material.
Interpretation of result
A
Table 1. is respectively organized the comparison (x ± s) of rat hemoglobin content
Annotate: with the iron deficiency matched group, compare * P<0.05; With combination drug compositions low dose group of the present invention, compare Δ P<0.05
Visible by table 1 result: after experiment, the Hb content of each dosage group rat of pharmaceutical composition of the present invention is significantly higher than the iron deficiency matched group, and the Hb content of the middle and high dosage group of pharmaceutical composition of the present invention rat is significantly higher than low dose group.
B
Table 2. is respectively organized the comparison (x ± s) of iron content in rat liver and spleen tissue
Annotate: with table 1
Visible by table 2 result: in the liver of rear each dosage group rat of pharmaceutical composition of the present invention of experiment and spleen, iron content is significantly higher than the iron deficiency matched group, and in the liver of middle and high dosage group rat and spleen, iron content is significantly higher than the iron deficiency matched group.
The prepared pharmaceutical composition FH-2 of embodiment 2,3 and FH-3 are carried out to efficacy testing with identical test mode, and it shows the therapeutic activity about the same with the prepared pharmaceutical composition of embodiment 1 equally.
In sum, gavage gives pharmaceutical composition of the present invention after 4 weeks, rat hemoglobin content significantly raises, supplementary copy invention pharmaceutical composition can obviously increase iron content in the liver of rat and spleen, and in the liver of middle and high dosage group rat and spleen, iron content is significantly higher than the iron deficiency matched group, show that combination drug compositions of the present invention has the excellent properties that improves nutritional anemia, has wide market prospect and medical value.
The performance test of Comparative Examples pharmaceutical composition
1, except using aforementioned pharmaceutical compositions D1-D6, with above-mentioned experimental technique, adopt high dose administration and identical mensuration mode (1) and carried out the effect experiment that the Comparative Examples pharmaceutical composition is used for the treatment of nutritional anemia, the results are shown in Table 3.
Table 3. Comparative Examples is respectively organized the comparison (x ± s) of rat hemoglobin content
2, except using aforementioned pharmaceutical compositions D1-D6, with above-mentioned experimental technique, adopt high dose administration and identical mensuration mode (2) and carried out the effect experiment for the treatment of nutritional anemia, the results are shown in Table 4.
Table 4. Comparative Examples is respectively organized the comparison (x ± s) of iron content in rat liver and spleen tissue
Result by table 3 and table 4 shows, gavage gives the Comparative Examples pharmaceutical composition after 4 weeks, and in the liver of rat hemoglobin content, rat and spleen, iron content raises to some extent, but all is starkly lower than middle and high dosage group.As can be seen here, pharmaceutical composition when not adding compound iron, auxiliary agent or additive all is difficult to produce the curative effect of obvious enhancing, and also all can not produce significant beneficial effect during any in lacking 4-methoxy cinnamic acid, p-Methoxybenzoic acid, 3-amylbenzene sodium acetate in auxiliary agent.
3, except pharmaceutical composition FH-1 and D1-D6, administration time were respectively outside 2 weeks, 3 weeks, with above-mentioned experimental technique, adopt high dose administration and identical mensuration mode (1) and carried out the effect experiment for the treatment of nutritional anemia, the results are shown in Table 5.
Table 5. is respectively organized relatively (x ± s) of rat hemoglobin content and the result of different dosing time
Result by table 5 shows, after two weeks, rat hemoglobin content just can obviously improve with embodiment F H-1, has rapid-action, the obvious advantage of amplification; And Comparative Examples D1-6 is after two weeks, the amplitude that rat hemoglobin content improves is little, and drug effect is slow.
Comprehensively above-mentioned, combination drug compositions of the present invention shows the quick remarkable efficacy of improving nutritional anemia by suitable selection and the particular combinations of component, and while changing any wherein a kind of component, corresponding effect is all by decrease, this has proved the synergistic function between them apparently, has obtained beat all effect.
The purposes that should be appreciated that these embodiment only limits the scope of the invention be used to the present invention being described but not being intended to.In addition; also should understand; after having read technology contents of the present invention, those skilled in the art can make various changes, modification and/or modification to the present invention, within these all equivalent form of values fall within the protection domain that the application's appended claims limits equally.
Claims (10)
1. combination drug compositions, described combination drug compositions is composited by the Radix Astragali, Radix Angelicae Sinensis, the Rhizoma Atractylodis Macrocephalae, Radix Glycyrrhizae, Poria, Carapax Trionycis, Rhizoma Pinelliae Preparatum, Radix Arnebiae (Radix Lithospermi), Flos Lonicerae, Solenognathus, Fructus Lycii, Caulis Spatholobi, compound iron, auxiliary agent and additive various ingredients, wherein, auxiliary agent is the mixture of 4-methoxy cinnamic acid, p-Methoxybenzoic acid, 3-amylbenzene sodium acetate, the ratio of mixture is 1:1-2:1-1.5, additive is the mixture of the chelating ferrous and maltodextrin of carbamoylglycine dipeptides, and the ratio of mixture is 1:1-1.5.
2. combination drug compositions as claimed in claim 1, it is characterized in that: in weight portion, its concrete constituent content is as follows:
。
3. combination drug compositions as claimed in claim 1 or 2, it is characterized in that: auxiliary agent is the mixture of 4-methoxy cinnamic acid, p-Methoxybenzoic acid, 3-amylbenzene sodium acetate, the ratio of mixture is 1:1:1, additive is the mixture of the chelating ferrous and maltodextrin of carbamoylglycine dipeptides, and the ratio of mixture is 1:1.
4. combination drug compositions as described as claim 1-3, it is characterized in that: described pharmaceutical composition is the form of oral liquid, tablet, pill.
5. as the preparation method of combination drug compositions as described in claim 1-4 any one, it is characterized in that: according to above-mentioned weight portion, take each component mix homogeneously, obtain described combination drug compositions.
6. preparation method as claimed in claim 5, it is characterized in that: Radix Astragali extract, Radix Angelicae Sinensis extract, Rhizoma Atractylodis Macrocephalae extract, Radix Glycyrrhizae extract, Poria extract, Carapax Trionycis extract, Rhizoma Pinelliae Preparatum extract, Radix Arnebiae extract, Flos Lonicerae extract, Solenognathus extract, Fructus Lycii extract, the preparation method of Caulis Spatholobi extract is: respectively above-mentioned medical material is pulverized after dry in the sun, adopting mass percent concentration is the ethanol of 50-60%, at 60-65 ℃ of lower reflux, extract, 3-5 hour, simmer down to extractum after reclaiming ethanol, drying again, pulverize, grind to form fine powder, cross 80 mesh sieves, thereby obtain respectively the extract of said medicine active component.
7. as the described preparation method of claim 5-6 any one, it is characterized in that: the preparation method of compound iron is: the chitosan of getting deacetylation >=95% is dissolved in the acetic acid solution that mass concentration is 1-3%, stir into transparent uniform solution, take the ammonium ferric sulfate with chitosan monomer equimolar amounts, soluble in water, stir, it is 1-2 that dilute sulfuric acid and ammonia are regulated its pH, under stirring, the ammonium ferric sulfate aqueous solution is slowly added in the acetic acid solution of chitosan, reaction 3-5h, after reaction finishes, separate out chitosan ferrum (III) coordination compound gel, staticly settle fully, centrifugalize, the lower sediment deionized water, the dehydrated alcohol cyclic washing does not measure the existence of Fe3+ to inspection, clean postprecipitation through lyophilization, obtain required compound iron.
8. as the described preparation method of claim 5-7 any one, it is characterized in that: the preparation method of auxiliary agent is: proportionally take 4-methoxy cinnamic acid, p-Methoxybenzoic acid, 3-amylbenzene sodium acetate mix homogeneously, obtain auxiliary agent.
9. as the described preparation method of claim 5-8 any one, it is characterized in that: the preparation method of additive is: get the 50-100g glycine and the 30-50g potassium cyanate mixes, add water 100-200ml, adding 2-3gKOH, after room temperature reaction is complete, with hydrochloric acid, be adjusted to pH=4-5, low temperature crystallization, filter to obtain the carbamoylglycine dipeptides; Get carbamoylglycine dipeptides 50-60g, ferrous sulfate 25-40g, add water 100-150ml, with sodium hydroxide, regulate pH=6-7, after 60-80 ℃ of heating in water bath 5-7h, filter, filtrate processing industry ethanol, separate out precipitation, and it is chelating ferrous that oven dry obtains the carbamoylglycine dipeptides; Then take by a certain percentage the chelating ferrous and maltodextrin mix homogeneously of carbamoylglycine dipeptides, obtain desired additives.
10. a described combination drug compositions is for the preparation of the purposes in treatment anemia medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103755600A CN103405603A (en) | 2013-08-26 | 2013-08-26 | Composite drug composition for treating anemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013103755600A CN103405603A (en) | 2013-08-26 | 2013-08-26 | Composite drug composition for treating anemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103405603A true CN103405603A (en) | 2013-11-27 |
Family
ID=49598677
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013103755600A Pending CN103405603A (en) | 2013-08-26 | 2013-08-26 | Composite drug composition for treating anemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103405603A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250996A (en) * | 2015-10-30 | 2016-01-20 | 上海善力健生物科技有限公司 | Biological agent for treating iron-deficiency anemia, preparation method thereof and purpose thereof |
| CN106038793A (en) * | 2016-08-09 | 2016-10-26 | 石本奖 | Miao ethnomedicine formula for treating hypotension |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872236A (en) * | 2005-05-30 | 2006-12-06 | 白璋华 | Medication for treating aplastic anemia |
| CN101342343A (en) * | 2008-08-27 | 2009-01-14 | 吉林华康药业股份有限公司 | Medicament composition for treating anemia |
| CN102988616A (en) * | 2012-11-21 | 2013-03-27 | 荣成市崖头美全口腔诊所 | Chinese medicinal composition for treating anemia |
| CN103083541A (en) * | 2013-02-02 | 2013-05-08 | 徐美玲 | Drug for treating anemia |
-
2013
- 2013-08-26 CN CN2013103755600A patent/CN103405603A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1872236A (en) * | 2005-05-30 | 2006-12-06 | 白璋华 | Medication for treating aplastic anemia |
| CN101342343A (en) * | 2008-08-27 | 2009-01-14 | 吉林华康药业股份有限公司 | Medicament composition for treating anemia |
| CN102988616A (en) * | 2012-11-21 | 2013-03-27 | 荣成市崖头美全口腔诊所 | Chinese medicinal composition for treating anemia |
| CN103083541A (en) * | 2013-02-02 | 2013-05-08 | 徐美玲 | Drug for treating anemia |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105250996A (en) * | 2015-10-30 | 2016-01-20 | 上海善力健生物科技有限公司 | Biological agent for treating iron-deficiency anemia, preparation method thereof and purpose thereof |
| CN106038793A (en) * | 2016-08-09 | 2016-10-26 | 石本奖 | Miao ethnomedicine formula for treating hypotension |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101905014B (en) | Traditional Chinese medicine compound composition for treating diarrhea of weaned piglets | |
| CN103251856B (en) | Traditional Chinese medicine preparation for benefiting Qi and nourishing blood and preparation method of traditional Chinese medicine preparation | |
| CN102397372A (en) | Medicinal composition and pharmaceutical preparation and application thereof to treating irritable bowel syndrome | |
| CN102961596B (en) | Traditional Chinese medicine composition for treating diabetes as well as preparation method and application of for traditional Chinese medicine composition | |
| CN102698180B (en) | Chinese medicine for radically treating stomach diseases | |
| CN103623134B (en) | A kind of Chinese medicine preparation preventing and treating Salmonella pullorum disease and preparation method thereof | |
| CN103006977A (en) | Yang-tonifying traditional Chinese medicine for generating and strengthening sperms and preparation method thereof | |
| CN103405603A (en) | Composite drug composition for treating anemia | |
| CN104127764A (en) | Traditional Chinese medicine to reduce uric acid and treat gout by regulating metabolism | |
| CN103919966B (en) | A kind of medicine treating acne | |
| CN108543044A (en) | A kind of combination medicine and application thereof for treating acne | |
| CN103272159A (en) | Chinese herbal preparation used for treating consumptive disease and preparation method thereof | |
| CN100363044C (en) | Medicine for treating acne and its preparation method | |
| CN103463248B (en) | One boar growth promotion Chinese medicine oral liquid | |
| CN102716353A (en) | Electuary for treating nephrotic syndrome | |
| CN109718352A (en) | A kind of Chinese medicine composition for treating indigestion and water sample rushes down | |
| CN102836197A (en) | Lactation-promoting Chinese medicinal composition and preparation method thereof | |
| CN103055280A (en) | Pure Chinese medicinal composition for treating indigestion of poultry and preparation method of pure Chinese medicinal composition | |
| CN101264208A (en) | Medicinal composition for treating stomach and intestine dysfunction and preparation thereof | |
| CN106106945A (en) | A kind of Ganoderma bagged infusion of American ginseng tea of enhancing immunity and preparation method thereof | |
| WO2017084169A1 (en) | Medicinal liquor for nourishing stomach and preparation method therefor | |
| CN103585461B (en) | Pure Chinese medicine composition for the treatment of poultry organization trichomoniasis and preparation method thereof | |
| CN117959401A (en) | Traditional Chinese medicine composition for treating rheumatic bone diseases and preparation method thereof | |
| CN103239564A (en) | Chinese medicine effective part composition for treating chronic nephritis and preparation method of Chinese medicine effective part composition | |
| CN102370733B (en) | A kind of compound Chinese medicinal preparation treating ulcerative colitis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20131127 |